Apyx Medical Past Earnings Performance

Past criteria checks 0/6

Apyx Medical's earnings have been declining at an average annual rate of -9.4%, while the Medical Equipment industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 14.3% per year.

Key information

-9.4%

Earnings growth rate

-9.0%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate14.3%
Return on equity-254.7%
Net Margin-58.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Apyx Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:BOV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2449-28465
30 Jun 2449-28485
31 Mar 2450-23485
31 Dec 2352-19495
30 Sep 2350-15485
30 Jun 2347-16485
31 Mar 2344-21475
31 Dec 2245-23485
30 Sep 2249-19484
30 Jun 2251-18484
31 Mar 2252-16474
31 Dec 2149-15444
30 Sep 2143-15404
30 Jun 2138-14374
31 Mar 2131-15344
31 Dec 2028-12344
30 Sep 2025-16344
30 Jun 2025-16354
31 Mar 2028-16364
31 Dec 1928-20354
30 Sep 1926-18343
30 Jun 1922-15293
31 Mar 1919-14263
31 Dec 1817-11223
30 Sep 1814-10182
30 Jun 1813-12172
31 Mar 185-15172
31 Dec 1710-14172
30 Sep 17-12-19151
30 Jun 17-4-17151
31 Mar 1737-4203
31 Dec 169-12151
30 Sep 1635-5183
30 Jun 1633-5182
31 Mar 1631-6182
31 Dec 15308172
30 Sep 15294172
30 Jun 15283162
31 Mar 15274162
31 Dec 1428-18131
30 Sep 1426-18141
30 Jun 1425-15111
31 Mar 1424-16111

Quality Earnings: BOV is currently unprofitable.

Growing Profit Margin: BOV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BOV is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.

Accelerating Growth: Unable to compare BOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: BOV has a negative Return on Equity (-254.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 07:21
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apyx Medical Corporation is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sam EiberBTIG
Matthew HewittCraig-Hallum Capital Group LLC
David TurkalyJMP Securities